Jul 5, 2024, 02:47
A new standard for treating limited-stage small cell lung cancer – Sarah Cannon Research Institute
“Dr. David R. Spigel recently shared research on durvalumab and how it has set a new standard for treating limited-stage small cell lung cancer, offering improved survival rates for patients. Explore the impactful findings from the ADRIATIC trial here: [ADRIATIC Trial: A New Beginning For The Treatment of LS-SCLC].”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19